Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb).
Ran JinAdesuwa S OgbomoNeil A AccorttLincy S LalGeetanjali BishiDarcie SandschaferJerome H GoldschmidtPublished in: Therapeutic advances in medical oncology (2023)
In this real-world cohort of mCRC patients who were treated 1L with a bevacizumab biosimilar (bevacizumab-awwb), the clinical effectiveness and tolerability data were as expected and consistent with previously published findings from real-world studies of bevacizumab RP in mCRC patients.